Grape King
葡萄王生技股份有限公司
Grape King is a Taiwan TWSE-listed biotechnology company; its most advanced asset is GKAC (Phase 2 study, Nonalcoholic fatty liver disease), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| GKAC | — | Phase 2 study | Nonalcoholic fatty liver disease | United States | — | Company disclosure |
Key events
No verified events in the past twelve months.